
WilmerHale Advises Potenza in Acquisition by Astellas

JANUARY 4, 2019

On December 14, 2018, Astellas Pharma Inc. announced the closing of its acquisition of Potenza Therapeutics, Inc. The acquisition comes from a successful result of a collaboration agreement entered into in 2015 to build a portfolio of novel immune-oncology therapies. Through this research collaboration, Astellas and Potenza have discovered and developed three novel investigational drugs with the potential to treat various cancers that are non-responsive or resistant to the current generation of immune-oncology therapies.

The WilmerHale team representing Potenza in this transaction is led by [Rosemary Reilly](#) and includes [Mark Nylen](#), [Michael Lopes](#), [Elizabeth Mayo](#) and Jenny Moore.

[Read more about the acquisition.](#)